Characterization of EIF2Be and Its Interaction with RGS2 by Xue, William H
Western University 
Scholarship@Western 
Electronic Thesis and Dissertation Repository 
6-19-2012 12:00 AM 
Characterization of EIF2Be and Its Interaction with RGS2 
William H. Xue 
The University of Western Ontario 
Supervisor 
Dr. Peter Chidiac 
The University of Western Ontario 
Graduate Program in Pharmacology and Toxicology 
A thesis submitted in partial fulfillment of the requirements for the degree in Master of Science 
© William H. Xue 2012 
Follow this and additional works at: https://ir.lib.uwo.ca/etd 
 Part of the Pharmacology Commons 
Recommended Citation 
Xue, William H., "Characterization of EIF2Be and Its Interaction with RGS2" (2012). Electronic Thesis and 
Dissertation Repository. 612. 
https://ir.lib.uwo.ca/etd/612 
This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted 
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of 
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca. 
  
 
 
CHARACTERIZATION OF EIF2Bε AND ITS INTERACTION WITH RGS2  
(Thesis format: Monograph) 
 
By 
 
 
William Xue 
 
 
Graduate Program in Physiology and Pharmacology 
 
A thesis submitted in partial fulfillment 
of the requirements for the degree of 
Master of Science 
 
 
The School of Graduate and Postdoctoral Studies 
The University of Western Ontario 
London, Ontario 
 
 
© William Xue 2012 
 
 
 
 
 
  
ii 
 
 
THE UNIVERSITY OF WESTERN ONTARIO 
SCHOOL OF GRADUATE AND POSTDOCTORAL STUDIES 
 
 
CERTIFICATE OF EXAMINATION 
 
 
Supervisor 
 
______________________________  
Dr. Peter Chidiac  
 
 
Supervisory Committee 
 
______________________________  
Dr. John Diguglielmo 
 
______________________________  
Dr. Stanley Dunn 
Examiners 
 
______________________________  
Dr. Andy Babwah 
 
______________________________  
Dr. Sean Cregan  
 
______________________________  
Dr. Eric Ball 
 
 
 
______________________________  
Dr. Graham Wagner (GSR) 
 
 
The thesis by 
 
 
William Hui Xue 
 
entitled: 
 
CHARACTERIZATION OF EIF2Bε AND ITS INTERACTION WITH 
RGS2 
 
is accepted in partial fulfilment of the  
requirements for the degree of  
Master of Science 
  
 
Date__________________________ _______________________________ 
Chair of the Thesis Examination Board 
 
 
  
  
iii 
 
ABSTRACT 
 
 
RGS2 is a GTPase accelerating protein for Gαq and its expression can be upregulated in 
response to different types of stress. We recently showed that RGS2 can bind to the 
translation initiation factor, eIF2Bε, and decrease global protein synthesis. The objective 
of this study is to characterize the RGS2 binding domain of eIF2Bε, investigate the effect 
of phosphorylation on binding, and examine the functional consequences as a result of 
their interaction. To identify the RGS2 binding domain of eIF2Bε, I generated various 
truncated eIF2B-GST fusion proteins and used them in an in vitro pulldown assay. I 
hypothesized that phosphorylation of eIF2Bε will increase its binding to RGS2 and that 
eIF2Bε binding to RGS2 will decrease the GAP activity of RGS2.  The results of my 
study revealed that the binding domain lies within the C-terminal region of eIF2Bε, 
which is consistent with our previous yeast two-hybrid data. A highly conserved amino 
acid residue within this region (leucine 576) appeared to play an important role in binding 
to RGS2.  In addition, mutating the GSK3 phosphorylation site on eIF2Bε increased its 
binding to RGS2.  However in my hands, purified eIF2Bε did not inhibit GAP activity of 
RGS2, contrary to my hypothesis.   
 
 
 
 
 
 
 
 
 
 
KEYWORDS:  Regulator of G protein signaling (RGS) proteins; RGS2; G protein 
coupled receptors (GPCR); eukaryotic initiation factor 2B (eIF2B); protein synthesis 
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Chapter 1 
Literature Review 
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1.1 G-protein Coupled Receptors (GPCRs):  
G protein-coupled receptors (GPCRs) are a class of seven transmembrane domain 
proteins found in many types of animal cells and tissues.  They recognize and bind to 
activating ligands and in turn activate heterotrimeric G proteins by promoting GTP 
binding in exchange for GDP 
1
 (Figure 1.1). This leads to the activation of G proteins and 
initiation of downstream signaling cascades.  GPCRs makes up the largest family of 
membrane proteins with around 800 human GPCRs known to exist, of which over half 
are olfactory receptors and about 340 of them non-olfactory receptors 
2
.  GPCRs are 
multifaceted in that they are involved in a number of physiological processes such as 
mediating signals for hormones, neurotransmitters, ions, photons, and other activators.  
GPCRs in vertebrates are generally classified into five different families, each according 
to structural and sequence similarities.  They are the rhodopsin, secretin, glutamate, 
adhesion and frizzled/taste2 receptor families.  The largest of these, the rhodopsin family 
is the most diverse and comprises several subfamilies, with each member possessing 
conserved sequence motifs and hence structural similarities.  However despite their 
similarities, each GPCR  exhibits its own expression pattern and unique signaling 
pathways via different subtypes of G-proteins as well as G-protein independent functions 
and regulatory processes 
3
.     
 
1.2 G Proteins:  
 Heterotrimeric G-proteins are membrane bound proteins comprising three 
subunits; alpha, beta and gamma (Gα, Gβ and Gγ) (Figure 1.1).  The Gα subunit is able to 
bind to GTP and activate downstream signaling pathways. Upon hydrolysis of GTP to 
3 
 
 
 
GDP, it is inactivated 
1
 
4.  The various Gα subunits are categorized into four classes; Gs 
which stimulates adenylyl cyclase, Gi which inhibits adenylyl cyclase, Gq which 
activates phospholipase Cβ, and G12/G13 which regulates Rho GEFs 5. The Gβ and Gγ 
subunits form a stable dimer (Gβγ) that binds and stabilizes Gα-GDP by slowing GDP 
dissociation.  Notwithstanding this, Gβγ is also required for the activation of Gα by 
GPCRs.  In addition, Gβγ can also bind to effectors and participate in signaling pathways 
such as ion channels, PI-3 kinase, and guanine nucleotide exchange factors for (GEFs) 
for small G-proteins 
6
.   
 
1.3 Regulator of G-protein Signaling (RGS) Proteins:  
Regulator of G-protein signaling (RGS) proteins are a class of proteins that 
attenuate G-protein signaling by binding to G-proteins (Figure 1.1), and accelerating the 
rate of GTP hydrolysis to GDP via a conserved 120 amino acid RGS domain (also known 
as the RGS box).  This function limits the duration of G-protein signaling and hence fine 
tunes the degree to which the signaling pathway will elicit a response.  To date over 
twenty RGS proteins have been discovered, and they are categorized into five 
subfamilies.  They are B/R4, RZ, R7, R12, and RL; categorized based on similarities in 
regions within the RGS domain as well as outside 
7
.  Four of the five subfamilies are 
known to have GTPase accelerating activity, and of those most are able accelerate 
GTPase activity of the Gi subfamily, and some being able to attenuate activity of the Gq 
subfamily 
8
.  No RGS proteins that have been discovered to date can accelerate Gs 
subfamily GTPase activity although RGS2 can interact with certain isoforms of adenylyl 
cyclases to inhibit Gs mediated signaling 
9
. 
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Figure 1.1 GPCR and G-proteins 
A GPCR is activated upon binding to a ligand, which stabilizes the conformation 
favourable towards binding of Gα and catalyzes guanine nucleotide exchange.  Upon 
binding to GTP, the Gα is activated and acts on downstream effectors, while Gβγ acts on 
its distinct effectors.  Gα possesses intrinsic GTPase activity, however upon binding to a 
RGS protein the GTP hydrolysis is accelerated and the duration of the signaling is 
shortened. 
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1.4 Gq/11 Signaling: 
 Angiotensin II, catecholamines, and endothelin-1 are among the endogenous 
agonists that bind to GPCRs that couple to Gαq/11 subfamily G-proteins.  Upon 
activation Gαq/11 in turn activates phospholipase Cβ (PLCβ), leading to cleavage of 
phosphatidylinositol 4,5-bisphosphate (PIP2) and production of inositol trisphosphate 
(IP3) and diacylglycerol (DAG) 
10
.  Production of IP3 leads to release of stored 
intracellular calcium mediated through the direct binding to IP3 receptor localized on the 
endoplasmic reticulum. Intracellular calcium in turn activates various intracellular 
proteins including calcineurin and NFAT transcription factors, while conventional 
Protein Kinase C (PKC) is activated by calcium and DAG, and it affects MAPK signaling 
through kinases such as ERK 1/2, JNK and p38 
10
. 
 
1.5 RGS2:  
RGS2 belongs to the B/R4 subfamily of RGS proteins and is unique among others 
in that it selectively inhibits Gαq and Gαs signaling 11. The human form contains 211 
amino acids and its structure comprises a short N-terminal amphipathic region 
responsible for cell localization 
12
 followed by an RGS box, which is responsible for its 
GTPase accelerating protein (GAP) activity, and a short C-terminus (Figure 1.2).  
However in recent years, non-canonical functions of RGS proteins have been discovered 
and characterized.  Besides its GAP function, RGS2 can interact with the cation channel 
TRPV6 and also with tubulin via its N-terminal region. Both of these novel RGS2 
interactions map to amino acid residues that lie outside of the RGS box 
13
 
14
.  In addition 
RGS2 can bind to eIF2Bε and thereby inhibit the translational machinery 15.  It is this 
6 
 
 
 
non-canonical function of RGS2 that our lab has taken recent interest in and the focus of 
this thesis is to further understand the interaction between RGS2 and eIF2B.   
The expression of RGS2 can be upregulated by Gαq and Gαs mediated signals but 
its expression can also be induced by various forms of cellular stress including, heat 
shock, DNA damage, viral infection, and oxidative stress 
16
 
17
.  The ability and the role of 
RGS2 in attenuating G protein signaling have been well characterized, however its role in 
response to cellular stress has just begun to be deciphered.    The working hypothesis in 
our laboratory is that the upregulation of RGS2 in cellular stress serves to decrease the 
rate of mRNA translation and thus conserve energy and resources.       
 
 
 
 
 
 
 
 
 
 
7 
 
 
 
 
 
Figure 1.2 List of different RGS proteins known to date 
18
 
 
RGS2 belongs to the R4 subfamily of RGS proteins, possessing short amphipathic motif 
near the N-terminus followed by the RGS box.   Compared to other subfamily of RGS 
proteins, RGS2 is relatively small and seemingly has fewer motifs.  However in recent 
years, more binding partners for RGS2 have been discovered, revealing its versatility and 
complexity beyond its known role as a GAP. 
 
Figure obtained from Circulation Research (2005); 96(4):401-11. Article, Multi-tasking 
RGS proteins in the heart: the next therapeutic target?   
Riddle EL, Schwartzman RA, Bond M, Insel PA 
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1.6 RGS2 and its role in the cardiovascular system 
RGS proteins are expressed throughout the body, with each having a different 
expression profile depending on the tissue type 
13
 
19
.  RGS2 especially is ubiquitously 
expressed throughout the cardiovascular system 
20
, where it plays an important role in 
mediating smooth muscle relaxation 
21
 and attenuating hypertrophic pathways in the 
heart, which is thought to occur via its interaction with Gq and Gs signaling pathways 
(Figure 1.3) 
22
.  RGS2
-/- 
mice have been shown to be hypertensive with increased agonist 
dependent Gq signaling 
23
 
21
 
24
.  Studies with aortic banding in mice have shown that the 
procedure leads to an increase in expression of RGS2 
25
, while we  have shown that 
overexpression of RGS2 attenuates hypertrophic responses in cultured cardiomyocytes 
26
.  
However others have observed an eventual decrease in RGS2 protein expression levels as 
hypertrophy progresses, potentially due to desensitization of RGS2 upregulation due to 
prolonged duration of Gq/11 signaling 
27
 
28
, although even then RGS2 would still be 
expected to be one of the predominant RGS proteins in the myocardium.  Ultimately, 
hypertrophic responses are the direct result of increased protein synthesis 
29
, and the 
attenuation of this process by RGS2 is thought to be mediated through its regulatory 
effects on Gq and Gs pathways 
26
.  Notably, it has been shown that eIF2B is required for 
β-adrenergic receptor mediated hypertrophy, and this can be regulated by glycogen 
synthase kinase 3β (GSK3β) via phosphorylation on serine 540 29.  However recently as 
mentioned above, our lab has demonstrated that RGS2 also may have a direct role in 
regulating translation via its interaction with translation initiation factor eIF2B 
15
. 
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Figure 1.3 Expression of RGS2 in cardiovascular system 
30
 
Although RGS2 is found throughout the body, it is highly expressed in the cardiovascular 
system.  RGS2 is acutely upregulated in response to α1-adrenergic activation in cultured 
ventricular myocytes, and in turn attenuates the hypertrophic response in these cells.      
 
Figure obtained with permission from Clinical Science (2009) 116, (391–399) article, 
RGS proteins: Identifying new GAPs in the understanding of blood pressure regulation 
and cardiovascular function 
Steven Gu, Carlo Cifelli, Sean Wang and Scott P. Heximer  
 
 
 
 
10 
 
 
 
1.7 Protein Synthesis:  
 
Protein synthesis is a complex cellular process, which involves the coordination 
of multiple factors like mRNA, tRNA, ribosomes, and accessory factors in order to 
synthesize new proteins.  Translation is categorized and divided into three steps; 
initiation, elongation and termination.  In each of steps there are many known protein 
factors which help coordinate the positioning of ribosomes, tRNA and mRNA and help 
execute the addition of amino acids to the nascent peptide chain 
31
.  Of the three, 
initiation is considered to be the rate limiting step of translation and hence it is not 
surprising that multiple initiation factors are involved in this process 
32
.  Dysregulation of 
the protein synthesis machinery can contribute to the development of diseases like 
cardiac hypertrophy, cancer, neurodegeneration and diabetes 
33
.  Therefore it is important 
that the regulation of translation be explored and investigated in order to better 
understand the complex physiology and pathophysiology of diseases where protein 
synthesis is altered. 
 
1.8 Translation initiation and eIF2B:  
In translation initiation, methionine tRNAi binds to eukaryotic initiation factor 2 
(eIF2), a heterotrimeric G protein comprising α, β, and γ subunits.  Unlike membrane 
bound heterotrimeric G-proteins, eIF2 resides in the cytosol and GTP binds to its γ 
subunit.  eIF2 is active when it is bound to GTP, and it escorts the initiator methionyl 
tRNA to the 40s (small subunit) ribosome.  The mRNA then is recruited to the 40s 
ribosome by eIF4s, forming the initiation complex.  Once the complex is formed, eIF5 
11 
 
 
 
promotes the hydrolysis of GTP by eIF2, leading to release of bound initiation factors 
and recruitment of the 60s subunit to begin peptide elongation (Figure 1.4) 
32
.   
GDP bound to eIF2 dissociates at a slow rate as it has higher affinity for GDP 
than for GTP 
34
. Eukaryotic initiation factor 2B (eIF2B) is a heteropentameric protein that 
plays a key role in protein translation initiation in that it acts as a guanine nucleotide 
exchange factor (GEF) for eIF2. Once GDP is exchanged for GTP, eIF2 can be activated 
again to begin another round of initiation (Figure 1.4).   eIF2B consists of five subunits; 
α, β, γ, δ, and ε.  α, β, and δ subunits share similar sequence motifs, which are known to 
interact with α subunit of eIF2 and play a regulatory role in controlling eIF2B activity.  γ 
and ε on the other hand form their own subcomplex to facilitate its catalytic activity.  
However, it is the ε subunit alone that possesses the ability to catalyze nucleotide 
exchange 
35
.   
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Figure 1.4 Translation initiation 
Translation is initiated by eIF2 binding to initiator methionyl tRNA and recruiting it to 
the 40s ribosome.  The mRNA is then brought by eIF4G, followed by GTP hydrolysis 
and the release of all factors, allowing the 60S ribosome to bind to 40S and start 
elongation.  eIF2 has higher affinity for GDP than for GTP, and therefore eIF2B acts as a 
guanine nucleotide exchange factor and indirectly restores the eIF2-GTP form.      
 
 
 
 
13 
 
 
 
1.9 Regulation of eIF2B by eIF2 
The rate of nucleotide exchange on eIF2 is one of the key rate limiting steps in 
translation, making eIF2B a crucial protein to regulate in order to control the overall rate 
of protein synthesis 
32
.  The most thoroughly studied and well understood mechanism of 
such regulation involves the phosphorylation of eIF2.  During glucose and amino acid 
starvation, oxidative stress, endoplasmic reticulum (ER) stress, or viral infection, 
corresponding stress-activated kinases in the cell become activated in response.  These 
kinases include General Control Nondepressible (GCN2), Protein kinase-like ER kinase 
(PERK), Heme-regulated inhibitor kinase (HRI), and Protein kinase R (PKR), all of 
which converge to phosphorylate the highly conserved serine 51 residue on the alpha 
subunit of eIF2 (Figure 1.5) 
36
 
37
 
38
 
39
.  When eIF2 is phosphorylated, it becomes a 
competitive inhibitor of eIF2B by binding at an even higher affinity than that of 
nonphosphorylated eIF2 
34
.  Since eIF2 is usually found in greater abundance than eIF2B 
in the cell, phosphorylated eIF2s can easily sequester eIF2B and prevent it from 
interacting with nonphosphorylated eIF2 and thereby decrease the rate of global protein 
synthesis 
40
 . 
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Figure 1.5 Regulation of protein synthesis by eIF2 
41
 
In response to different kinds of stress, different stress kinases converge and 
phosphorylate serine 51 on eIF2α.  The phosphorylated form of eIF2 binds to eIF2B with 
higher affinity and sequesters eIF2B from non-phosphorylated eIF2.  eIF2 reactivation 
slows down as a result and thus the initiation rate is decreased. 
 
Figure obtained with permission from Cell Cycle. 2008 May 1;7(9):1146-50. Article, 
PERK and PKR: Old kinases learn new tricks.   
Raven JF, Koromilas AE. 
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1.10 Interaction between eIF2 and eIF2B 
 eIF2 is a heterotrimeric G-protein comprising three subunits; α, β and γ, with the γ 
subunit being able to bind to GTP.  eIF2B is a heteropentameric protein containing 5 
subunits; α, β, γ, δ and ε.  As mentioned above, the α subunit contains the conserved 
serine 51 which can be phosphorylated by different kinases under stress 
42
, and in turn the 
phosphoserine interacts with α, β and δ subunits of eIF2B 43.  This is in addition to the 
interaction that already occurs under non-stressed conditions.   
  
Under normal conditions, interaction between eIF2 and eIF2B involves distinct 
motifs found in the β subunit of eIF2 and the ε subunit of eIF2B.  eIF2 β possesses three 
lysine rich motifs called the lysine boxes localized near its N-terminus (Figure 1.6)
44
.  
When these motifs were mutated to alanines, the interaction between eIF2β and eIF2B ε 
was markedly decreased.  Conversely, eIF2Bε possesses acidic and aromatic motifs near 
its C-terminus and when these were mutated to alanines, the binding between the two was 
decreased 
44
.  Therefore it is thought that these lysine boxes on eIF2β form ionic 
interactions with the acidic and aromatic residues on eIF2Bε. 
The catalytic region on eIF2Bε responsible for its guanine nucleotide exchange 
ability contains highly conserved residues throughout human, mammalian, plant and 
yeast species 
45
.  Among all species, residues glutamic acid 577 and leucine 576 and 
tryptophan 709 (in human sequence) are especially important for interaction and function 
(Figure 1.6).  When L576 of eIF2Bε is mutated to alanine, interaction between the 
catalytic portion of eIF2Bε and eIF2β and γ becomes impaired with the effect more 
pronounced on the interaction with the γ subunit 46.  Mutation of W709 to alanine on the 
16 
 
 
 
other hand almost completely destroyed the interactions of eIF2Bε with both eIF2β and -
γ.  E577 of eIF2Bε also was mutated to different residues including alanine, aspartic acid, 
arginine, and lysine, with all mutations significantly reducing the affinity of eIF2Bε to 
eIF2 with the exception of the alanine mutation.    Although the E577A mutant still 
bound to eIF2 in yeast, the ability of the mutant to catalyze guanine nucleotide exchange 
was significantly decreased, and the growth of yeast was also impaired compared to wild 
type control 
46
.  Taken together, these results show that E577 is important for the catalytic 
activity of eIF2Bε, while L576 and W709 are important for protein-protein interaction.  
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Figure 1.6 Interaction between eIF2 and catalytic domain of yeast eIF2Bε 46 
eIF2 binds to the C-terminal domain of yeast eIF2Bε.  Acidic motifs on eIF2Bε interact 
with lysine boxes on eIF2 β, while residue W699 (709 in humans) interacts with both 
eIF2β and -γ.  Residue E569 (577 in humans) is important for interacting with GDP 
bound eIF2γ and plays an important role in nucleotide exchange.   
 
Figure obtained from Molecular Cell Biology (2007) Jul;27(14):5225-34. Critical 
contacts between the eukaryotic initiation factor 2B (eIF2B) catalytic domain and both 
eIF2beta and -2gamma mediate guanine nucleotide exchange.  
Mohammad-Qureshi SS, Haddad R, Hemingway EJ, Richardson JP, Pavitt GD. 
 
 
 
 
18 
 
 
 
1.11 Regulation of eIF2B by RGS2 
From previous work in our lab, a possible interaction between RGS2 and 
eukaryotic initiation factor 2B (eIF2B), a heteropentameric protein, was identified based 
on yeast two-hybrid screen results.  The sequence that was obtained from the screen 
contained 45 residues that matched exactly to a string of residues found near the C-
terminus of eIF2Bε, the catalytic subunit of the eIF2B 15.   We confirmed this interaction 
at the protein level by co-immunoprecipitating overexpressed eIF2Bε and purified RGS2 
as well as the endogenous proteins in osteoblast-like osteosarcoma (UMR-106) cells 
15
.  
In addition RGS2 was able to decrease GEF activity of eIF2Bε on eIF2 in a dose 
dependent manner, suggesting competition between eIF2 and RGS2 for binding to 
eIF2Bε 15.  Experiments from in vitro translation assays revealed that RGS2 was able to 
decrease translation efficiency by approximately 75% compared to control, while 
decrease in protein synthesis by 25-40% compared to control was observed in cell based 
leucine incorporation assays.   
The eIF2Bε binding domain on RGS2 was eventually mapped to thirty seven 
amino acids that overlap with the beginning of the RGS box 
15
.  Subsequently a peptide 
was synthesized according to this region, and it was able to exert inhibitory effect on 
protein synthesis to a similar extent as full length RGS2 
15
.  This discovery has led us to 
further research into the area of translation, and the role of RGS2 in regulating protein 
synthesis. 
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1.12 Structure of eIF2Bε and putative RGS2 binding domain 
 To date there is no crystal structure of the entire eIF2Bε molecule available.  
However, the structure of approximately the last two hundred amino acids of the C-
terminal domain has been elucidated 
47
.  The protein structure comprises eight alpha 
helices that are compacted in a globule.  The forty five amino acid putative RGS2 binding 
domain on eIF2Bε coincidently lies within the first two and half helices of this structure 
(Figure 1.7).  In addition it overlaps with the catalytic region described previously by 
Pavitt et al., which contains highly conserved residues that are important for binding to 
eIF2 and guanine nucleotide exchange 
48
.     
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Figure 1.7 Putative RGS2 binding domain 
45
 
47
 
Putative RGS2 binding domain lies near the C-terminal region of human eIF2Bε.  The 
crystal structure of C-terminal domain eIF2Bε shows that this spans about 2 and half 
helices.  Within this region there are conserved residues such as human E577(H.s.) and 
L576(H.s.) which are known to be important for interaction with eIF2 (residue markers of 
the bottom figure are based on yeast sequence).   
 
Crystal structure obtained from Protein and Cell (2010) Jun;1(6):595-603. Crystal 
structure of the C-terminal domain of the ɛ  subunit of human translation initiation factor 
eIF2B.  
Wei J, Jia M, Zhang C, Wang M, Gao F, Xu H, Gong W. 
 
Bottom figure obtained from Journal of Biological Chemistry.  (2004) Mar 
12;279(11):10584-92.  Structure of the catalytic fragment of translation initiation factor 
2B and identification of a critically important catalytic residue. Boesen T, Mohammad 
SS, Pavitt GD, Andersen GR 
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1.13 Regulation of eIF2B by other eIF2-independent mechanisms: 
 The interaction between eIF2 and eIF2B and its regulation by eIF2 has been well 
characterized by different labs over the years.  However more recently, there have been 
several discoveries of eIF2-independent mechanisms whereby eIF2B can be regulated as 
well.  There are at least six phosphorylation sites that are known to regulate the activity 
of human eIF2B through its ε subunit.  These include regulation by glycogen synthase 
kinase 3 (GSK3) targeting serine 540, and its presumed priming kinase dual tyrosine 
regulated kinase (DYRK) on serine 544, resulting in decreased eIF2B activity 
49
.  Casein 
kinase 2 (CK2) targets two serines (717/718) situated at C-terminus, and the 
phosphorylation of these is required for efficient interaction between eIF2B and eIF2 
50
.  
The absence of available amino acids for translation can result in an unknown kinase 
phosphorylating serine 525, leading to a decrease in eIF2B activity 
51
.  Lastly RGS2 can 
also regulate eIF2B by binding to the ε subunit and interfering with guanine nucleotide 
exchange and translation efficiency (Figure 1.8) 
15
.  It is not surprising that eIF2B is a 
target of control by various mechanisms since it is one of the rate limiting steps in 
translation 
32
.  
 In this study, we were interested to see whether the changes in eIF2B activity 
associated with these phosphorylation events are accompanied by changes in affinity 
between eIF2B and RGS2.  For example when eIF2 is phosphorylated at serine 51 on its 
α subunit, its affinity for eIF2B is strengthened and hence turns it from being a 
productive binding partner to a competitive inhibitor 
34
.  Therefore it is of interest to us to 
investigate whether the phosphorylation state of these serines on eIF2Bε can affect 
RGS2-eIF2B interaction.       
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Figure 1.8 Regulation of eIF2B by eIF2 independent mechanisms 
eIF2B can be regulated by a mechanism independent of serine 51 phosphorylation on 
eIF2 α.  The ε subunit of eIF2B is subject to phosphorylation on multiple amino acid 
residues by different kinases, which can modulate its activity.  In addition RGS2 can also 
bind to eIF2Bε and decrease its activity. 
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1.14 Glycogen synthase kinase 3 (GSK3) 
 GSK3 as its name suggests phosphorylates glycogen synthase which decreases its 
activity during the absence of glucose and insulin signaling.  However this enzyme is 
known to play other roles in the cell including its inhibitory role in the Wnt/ β-catenin 
pathway (promotes cell proliferation) as well as the Hedgehog pathway (promotes 
angiogenesis and is anti-apoptotic).  GSK3 is constitutively active in most cell types, and 
is generally a negative regulator of its substrates.  It is unique compared to other kinases 
in that it may require the phosphorylation of a priming site four residue downstream of its 
target site before the substrate can be efficiently phosphorylated (Figure 1.9) 
52
.  
Substrates of this nature include glycogen synthase and eIF2Bε.  In case of eIF2Bε, in 
addition to the requirement of priming site, the presence of the last sixty residues are 
essential in order for GSK3 to efficiently interact and phosphorylate eIF2Bε 50.      
There are two mammalian isoforms of GSK3; GSK3α and GSK3β which are 
encoded by two distinct genes.  Both forms are structurally similar and comparable in 
size with GSK3α being 51 kDa while GSK3β is a 47 kDa protein.  They possess 98% 
homology within their kinase domain in rats but are only 36% identical in the last 76 C-
terminal residues.  Although both isoforms are structurally similar they are not 
functionally identical.  For example GSK3β knockout mice are embryonically lethal due 
to degeneration in liver from apoptosis in hepatocytes.  This means that GSK3α could not 
rescue the ablation of GSK3β and the phenotype is arising from the loss of the beta 
isoform 
52
.   
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Figure 1.9 Glycogen synthase kinase 3 
52
 
GSK3 is constitutively active and usually phosphorylates its substrate to deactivate it.  It 
is unique among kinases in that for certain substrates GSK3 will bind more efficiently if 
they are already primed by another kinase.  For eIF2Bε, in addition to the priming site the 
presence of last 60 amino acids is essential for binding to GSK3. 
 
       
Figure obtained with permission from Journal of Cell Science (2003) Apr 1;116(Pt 
7):1175-86. GSK-3: tricks of the trade for a multi-tasking kinase.  
Doble BW, Woodgett JR. 
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1.15 Regulation of eIF2B by GSK3 
 In addition to the phosphorylation of eIF2, eIF2B can also be regulated by GSK3 
when it phosphorylates a conserved serine residue on the ε subunit of eIF2B.  In the 
absence of insulin, GSK3 is constitutively active and is able to efficiently interact with 
eIF2Bε and phosphorylate it provided that phosphorylation of the priming site four 
residues downstream is already in place.  In addition to the priming mechanism, it seems 
that the presence of the last 60 amino acids of eIF2Bε is also essential in order for GSK3 
to bind as truncation of the C-terminus impaired the interaction 
50
.   This phosphorylation 
results in a decreased eIF2B activity and thus decreases the rate of translation 
49
 
53
.  This 
is thought to happen by decrease in the intrinsic GEF activity of eIF2Bε, rather than 
altering its binding to a regulator.  However this does not rule out a possibility whereby 
the phosphorylation event promotes a favorable interaction with another binding partner, 
resulting in stabilization of the less active conformation.   
In functional assays, RGS2 also inhibited protein translation, consistent with the 
observed co-immunoprecipitation of RGS2 and eIF2Bε and with results showing that 
RGS2 can inhibit the guanine exchange activity of eIF2Bε on eIF2 in a dose dependent 
manner 
15
.  However the trigger or the mechanism by which RGS2 is recruited to eIF2B 
is unknown, which led to the idea of investigating the relationship between regulation of 
eIF2B by GSK3 and regulation of eIF2B by RGS2. 
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1.16 Regulation of eIF2B by Casein Kinase 2 (CK2):  
CK2 is a kinase that is ubiquitously expressed in cells.  It is so far known to be 
involved in cell proliferation, transformation, apoptosis and senescence 
54
.  Wang et al. 
have discovered that eIF2B is also a target of phosphorylation by CK2, showing that 
such phosphorylation is actually important and necessary for efficient interaction between 
eIF2 and eIF2B 50.  The phosphorylation sites are located three amino acids from the C-
terminus in humans, and they are surrounded by acidic motifs on both sides.  Presumably 
the phosphorylation of the two serines strengthens the acidic motif, hence allowing 
eIF2Bε to better interact with the lysine boxes found on eIF2β.  Based on the observed 
ability of RGS2 to inhibit the GEF activity of eIF2B 15, it is plausible that RGS2 could 
be competing for binding to eIF2B with eIF2.  Therefore it would be interesting to 
investigate whether phosphorylation of the CK2 site might have an effect on binding 
between RGS2 and eIF2B. 
 
1.17 Regulation of eIF2B by serine 525: 
 During amino acid starvation, translation can be inhibited via phosphorylation of 
serine 51 on the α subunit of eIF2 and subsequent sequestration of eIF2B 55.  However 
the ε subunit of eIF2B can also be regulated by amino acid availability independent of 
eIF2α phosphorylation.  Serine 525 is found adjacent to a known phosphorylation site 
that is regulated by GSK3.  Although the identification of the kinase and phosphatase 
responsible for this site remains to be established, it is known that this site can regulate 
the activity of eIF2B in response to the relative abundance of amino acids 
51
.  When this 
site was mutated to alanine, eIF2B activity was greater than that of the wild type protein 
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in the absence of amino acids.  This suggests that in the absence of sufficient amino acid 
in the cell, this site is usually phosphorylated; leading to decreased activity of eIF2B 
while in the presence of abundant amino acids this site is dephosphorylated 
51
.   
This site also lies close to the putative RGS2 binding domain since it is adjacent to the 
GSK3 site, which itself lies thirteen amino acid upstream of the binding domain.  
Similarly to GSK3, the phosphorylation of this site results in decreased eIF2B activity.  It 
is of interest to investigate whether phosphorylation of this site may have any effect on 
eIF2Bε-RGS2 interaction.          
 
1.18 Rationale 
RGS2 possesses a region whose amino acid sequence bear 40% homology with 
that of the β subunit of eIF2 15.  eIF2β interacts with eIF2Bε and the eIF2β binding 
domain on eIF2Bε lies near its C-terminus.  In addition, eIF2γ interacts with the catalytic 
region of eIF2Bε and hence mutation of key residues within this region not only impairs 
GEF activity but also its interaction with eIF2 
51
.   Since RGS2 seems to be able to 
compete with eIF2 and disrupt GEF activity in a dose dependent manner 
15
, we 
hypothesized that the RGS2 binding domain on eIF2Bε may be near or partially 
overlapping with the eIF2 binding domain.  Together with previous yeast two-hybrid data 
we believe RGS2 binding domain on eIF2Bε comprises at least 45 amino acid region 
near the C-terminus and perhaps further extends to region N and C terminally.   
The binding between eIF2 and eIF2B has been investigated by other researchers, 
and from their research it was identified that eIF2Bε (the subunit which catalyzes 
exchange of nucleotide on eIF2) possess at least five phosphorylation sites, four of which 
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have been shown to regulate eIF2B activity and binding to eIF2 
50
.  Two of the 
phosphorylation sites are targeted by GSK3 and its priming kinase, while two others are 
phosphorylated by kinase called CK2.  GSK3 and its priming site are located about ten 
amino acids upstream of 45 amino acid putative RGS2 binding domain, while the CK2 
site is located at the C-terminus.  Therefore, it would be worthwhile first to investigate 
GSK3 site as it lies closer to the putative binding region. 
 
In addition to these regulatory mechanisms, our lab has found that RGS2 can 
interact with eIF2B and consequently reduce translational efficiency 15.  Therefore we 
planned to investigate whether the reciprocal is true; whether the binding of eIF2B to 
RGS2 may have an effect on the ability of RGS2 to promote GTP hydrolysis. 
 
 Therefore my hypothesis is that the phosphorylation of eIF2B will increase the 
binding of RGS2 to eIF2B, and that eIF2B binding to RGS2 will decrease GAP activity 
of RGS2. 
 
1.19 Objectives Overview: 
 
1. a) Identify the region(s) on eIF2Bε that interacts with RGS2 using an internal 
deletion method in order to assess the ability of mutant eIF2Bε  to interact with 
RGS2 
b) Express eIF2Bε and mutants in E.coli and purify the proteins in order to show 
and confirm its ability to directly interact with purified RGS2  
29 
 
 
 
c) Use an amino acid substitution method to further assess which residue(s) are 
important for binding. 
2. Identify phosphorylation sites on eIF2Bε that are near the region of interaction 
with RGS2, and assess their ability to influence the binding affinity by using point 
substitutions 
3. Investigate the functional consequence of eIF2Bε binding on RGS2 GAP activity  
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Chapter 2 
Methods 
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2.1 Reagents  
Plasmids encoding histidine-tagged wild-type human RGS2 were provided by Dr. J. 
Hepler (Emory University, Atlanta, GA).  pHM Plasmids encoding c-myc and histidine-
tagged human eIF2B subunits 
56
 were provided by Dr. C.G. Proud (University of British 
Columbia, B.C.).  The baculovirus encoding mouse M1 muscarinic receptor–G11 fusion 
protein 
57
 was provided by T. Haga (Hongo campus, University of Tokyo, Japan) 
58
.  
Protein A/G PLUS-agarose beads and anti-histidine antibody were purchased from Santa 
Cruz Biotechnology, Inc.  Anti c-myc antibody was purchased from Cell Signaling 
Technology.  HEK293 cells were used for transfection, E.coli XL1 blue for 
transformation, and E.coli BL21 (DE3) for protein purification.   
 
2.2 Cloning 
  pHM eIF2Bε internal deletion and pGEX 4T-1 eIF2Bε N terminal and C-terminal 
truncation constructs were made using inverse PCR using phosphorothioate-modified 
primers 
59
.  The primers (listed in Table 2.1) were designed flanking the sequences that 
needed to be excised.  Four phosphorothioate bases were incorporated twelve bases from 
the 5’ end, ensuring that the resulting overhang would be unique enough to complement 
one another. PCR reactions were carried out using pfu DNA polymerase with annealing 
temperatures at 55 °C for 1 min, while the extension was carried at 72 °C for 8 min for a 
total of 30 cycles.  Following PCR reaction, the resulting product was treated with 
exonuclease, which creates a 3’ overhang by digesting the bases from the 5’ end. Internal 
deletion mutants eIF2Bε Δ1,2,3 and Δ1 and Δ2 were made by excising amino acids 554-
598, 553-566, and 571-581 respectively.  N-terminal and C-terminal truncation mutants 
32 
 
 
 
eIF2Bε GST-300 version1, GST-300 version2, GST-200, GST-80 were made by excising 
amino acids 1-430, 6-436, 1-520, and 1-520/599-721 respectively.   Substitution mutants 
were made at L576W, Y585W, S540A, S544A, S540E and S544E.  The mutant plasmids 
were confirmed by DNA sequencing the region of deletion or substitution.  Although 
mutations from previous studies were numbered based on yeast eIF2Bε, we have used 
human eIF2Bε for our present study and therefore the residues numbering corresponds 
accordingly to human sequence. Subsequently, the plasmids were transformed into E.coli 
XL1 blue and purified using a mini-prep kit (Qiagen).  pHM and pGEX 4T-1 eIF2Bε 
single substitution mutants were made using site-directed mutagenesis.  Primers were 
designed flanking the desired base(s) that needed to be changed.  PCR reaction was 
performed followed by plasmid transformation into E.coli XL1 blue and purification 
using a mini-prep kit (Qiagen).   
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Table 2.1 List of primers used for mutagenesis 
A) Phosphorothioate primers were used to generate internal deletion mutants that were used in 
Figure 3.1. B) Phosphorothioate primers were used to generate internal deletion mutants that were 
used in Figure 3.2 C) Substitution mutants mimicking phosphorylation states were generated 
using site-directed mutagenesis.  These mutants were used in Figure 3.7 and 3.9 D) Substitution 
mutants that were used in Figure 3.6 were also generated using site-directed mutagenesis. 
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2.3 RGS2 purification 
N-terminal 10 polyhistidine tagged human RGS2 containing pET19b vector was 
expressed in E.coli BL21 (DE3) strain and purified via nickel affinity chromatography.  
First, 3 L of bacterial culture were incubated with vigorous shaking at 37°C to an OD600 
of 0.6-0.8. Expression of RGS2 protein was induced by the addition of 0.5 mM Isopropyl 
β-D-1- thiogalactopyranoside (IPTG) for 3 hrs before harvesting the bacteria by 
centrifugation.  Bacteria were resuspended in 50 ml of HEPES buffer (50mM HEPES, 
pH 8.0, 500 mM NaCl, 20 mM β-mercaptoethanol, 0.1 mM PMSF, 10 μg/ml leupeptin, 1 
μg/ml aprotinin, and 1% Triton X-100), and the suspension was sonicated at 10 Watts for 
4 x 15 second intervals with 30 seconds of cooling on ice in between.  The lysate was 
centrifuged at 15000 g for 30 min, and the supernatant was extracted.  A 50% slurry of 
equilibrated nickel resin (1 ml) was added to the supernatant and mixed on a rocking 
platform for 1.5 hrs at 4°C, followed by loading of the supernatant/slurry of beads onto a 
column, allowing the supernatant to flow through using gravity.  Then the beads were 
washed with 20 ml HEPES buffer supplemented with 20 mM imidazole twice and the 
protein was eluted with 500 μl HEPES buffer with 150 mM imidazole 4-5 times.  The 
eluates were pooled and dialyzed in 1L dialysis buffer (25 mM HEPES, pH 7.5, 500 mM 
NaCl, 2 mM DTT) for 6 hours, followed by exchange of old for fresh dialysis buffer, and 
then further dialyzed overnight.  Purified proteins were run on SDS-PAGE gel (see 
Figure 2.1) and found to be ≥75% pure with predicted size of ~26kDa and apparent size 
of ~30kDa.  Purified proteins concentrations were determined using the Bradford assay,
60
 
and were stored in aliquots at -80°C.  
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Figure 2.1 Purification of His-RGS2 from E.coli BL21 (DE3) 
The left panel shows the Coomassie stain after purification (4 µg), while the right panel shows the 
immunoblot to confirm the identity of the protein (1 µg).  Histidine RGS2 runs at an apparent size 
of 30 kDa, roughly consistent with its calculated molecular molecular weight of 26 kDa.  
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2.4 Purification of GST-eIF2Bε wild type and mutant proteins 
Human GST-eIF2Bε and mutant constructs containing pGEX vector were expressed in 
E.coli BL21 (DE3) strain and purified via glutathione sepharose affinity chromatography.  
First 4 L of bacterial culture were incubated with vigorous shaking at 37°C to an OD600 
of 0.6-0.8. Expression of the GST-fusion proteins was induced by the addition of 0.5 mM 
IPTG for 1 hr at 15°C before harvesting the bacteria by centrifugation.   Bacteria were 
resuspended in 50 ml of TRIS buffer (50 mM TRIS, pH 8.0, 100 mM NaCl, 20 mM β-
mercaptoethanol, 0.1 mM PMSF, 10 μg/ml leupeptin, 1 μg/ml aprotinin, and 1% Triton 
X-100), and the suspension was sonicated at 10Watts for 4 x 15 second intervals with 30 
second cooling on ice in between bursts. The lysate was centrifuged at 15000 g for 30 
min, and the supernatant was extracted.  A 50% slurry of equilibrated glutathione 
sepharose resin (1 ml) was added to the supernatant and mixed on a rocking platform for 
1.5 hrs at 4°C.  Subsequently the beads were centrifuged at 500 g and supernatant were 
removed, followed by five washes (5 ml) with TRIS buffer lacking Triton X-100 and 
centrifugation and aspiration of the supernatant.  The proteins were eluted with 500 μl 
elution buffer (50 mM TRIS, pH 7.5, 100 mM NaCl, 50 mM glutathione) and stored in 
aliquots at -80°C.  Protein concentrations were determined using the Bradford assay.  
Purification steps of GSTeIF2Be fusion proteins are illustrated in Figure 2.2. 
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C.  
 
D. 
 
Figure 2.2 Purification of GST-eIF2Bε and N/C-terminal truncation mutants 
A) Schematic of GST-fusion constructs B) Coomassie stain of GST-eIF2Bε purification.  Lysate 
contains all proteins from the cells, while supernatant after beads shows the presence of proteins 
in solution after the glutathione sepaharose beads were centrifuged.  Flow through denotes the 
presence of proteins in buffer after the first wash. C) Coomassie stain of GST-200 a.a.  (eIF2Bε-
521-721) purification (predicted size of 49kDa and apparent size of 50kDa). D) Coomassie stain 
of GST-80 a.a. (eIF2Bε-521-598) purification (predicted size of 38kDa apparent size of 38kDa) .  
GST-300 a.a. (eIF2Bε-431-721) was also purified in the same manner but is not shown (predicted 
size of 64kDa and apparent size of 64kDa). 
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2.5 Co-immunoprecipitation assay 
10 cm round culture plates containing HEK 293 cells were transfected using 
lipofectamine with plasmids (20 µg) encoding eIF2Bε or mutants thereof, followed by 48 
hrs incubation at 37 °C with 5% carbon dioxide.  The cells were lysed with 500 µl lysis 
buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 1% Triton X-100, 0.1 mM PMSF, 10 
μg/ml leupeptin, 1 μg/ml aprotinin) and centrifuged at 13,000 rpm (17,400 g) for 10 min 
to pellet cell debris and lysates were extracted.  10 μg of purified histidine-tagged RGS2 
were mixed with cell lysate containing the overexpressed protein and were incubated for 
1 hr at 4 °C.  Myc-antibody and protein A/G beads were added to the mixture and 
incubated for 3 hrs, followed by three washes with lysis buffer (700 µl) consisting of 
centrifugation, aspiration of supernatant and finally suspension in 2x Laemmli sample 
buffer (50 mM Tris-Cl pH 6.8, 2% SDS, 10% glycerol, 2.5% β-mercaptoethanol, 0.01% 
bromophenol blue). 
 
2.6 GST pull down assay 
150 nM or 300 nM of purified GST-fusion proteins were mixed with 1 μM of purified 
RGS2 in 200 µl of binding buffer (50 mM TRIS, pH 7.5, 250 mM NaCl, 0.1% Tween, 
0.1 mM PMSF, 10 μg/ml leupeptin, 1 μg/ml aprotinin) and incubated for 30 min at 4 °C 
on a eppendorf tube rotator.  Glutathione sepharose beads were then added to the mixture 
for another 1 hr before washing with binding buffer three times by centrifuging the beads, 
aspirating the supernatant and resuspension in buffer.  Resulting beads were suspended in 
2x Laemmli sample buffer. 
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2.7 Immunoblot analysis 
Protein samples in Laemmli buffer were incubated at 99 °C for 5 min, followed by SDS-
PAGE and transfer for 1 hr using semi-wet transfer machine (Bio Rad) to polyvinylidene 
fluoride membrane.  Probing for the presence of the proteins was done using anti-
histidine or anti-GST primary antibodies with horse radish peroxidase conjugated 
secondary antibodies. Blots were then visualized by using a chemiluminescent substrate 
(LumiGLO Reserve; Kirkegaard & Perry Laboratories, Inc.) and a camera-based imaging 
system (Fluorchem 8000; Alpha Innotech Corporation).  Photoshop (CS2; Adobe) was 
used to fine tune the brightness and contrast only.   
 
2.8 GTP hydrolysis assay 
Receptor- and RGS protein-stimulated G protein GTPase activity was assayed essentially 
as described previously 
11
 
15
. Briefly, Sf9 insect cells were grown to a density of 2 × 10
6
 
cells/ml followed by infection with baculoviruses encoding Gβ1, Gγ2, and an M1 
muscarinic receptor-Gα11 fusion protein. At 48 hrs after infection, cells were centrifuged 
at 228 g for 5 min, resuspended in phosphate buffered saline (PBS), and centrifuged 
again. The resulting pellet was resuspended in one third of the original volume of lysis 
buffer (20 mM Tris, pH 8.0, 0.1 mM PMSF, 10 μg/ml leupeptin, and 1 μg/ml aprotinin) 
and incubated on ice for 15 min. The cells were lysed using a homogenizer (Polytron; 
Brinkmann Instruments) and centrifuged at 500 g for 10 min. to remove debris and 
unbroken cells. The supernatant was retained and centrifuged for 30 min at 48,000 g. The 
supernatant from this centrifugation was discarded, and the pellets were resuspended in 
0.01 volume of lysis buffer and stored at -80°C.   
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Membranes were assayed for 100 μM carbachol-stimulated GTP hydrolysis for 5 min at 
30°C in the absence and presence of the indicated RGS proteins and GST-fusion proteins.  
The reaction buffer contained 10
6
 cpm/assay γ-[32P]GTP, 20 mM Hepes, pH 7.5, 1 mM 
EDTA, 1 mM DTT, 200 nM GTP, 0.5 mM ATP, 0.1 mM PMSF, 1 μg/ml aprotinin, 10 
μg/ml leupeptin, 0.1 mM ascorbic acid, 10 mM NaCl, and 2 mM MgCl2 making up a 
total reaction volume of 60 μl.  The reaction was then incubated in a water bath at 30 °C 
for 5 min. Nonspecific GTPase activity was defined as that in the presence of membranes 
plus the inverse agonist, 10 μM tropicamide, and these values were subtracted from 
carbachol stimulated activity to yield the specific agonist and receptor-dependent signal. 
GTP hydrolysis reactions were terminated by the addition of 940 µl 5% Norit (activated 
charcoal) in 50 mM NaH2PO4, pH 3.0, 4 °C. The reaction mixture was centrifuged at 
3,000 g for 10 min, and 600 µl of supernatant containing 
32
Pi was recovered from the 
reaction tube.  Radioactivity was measured on a liquid scintillation counter (Packard Tri-
Carb 2900TR; PerkinElmer). 
 
2.9 Statistical analysis 
Data are presented as means with standard error for (n) values as indicated in each figure.  
Statistical significance was determined using unpaired student T-test or one-way 
ANOVA test (GraphPad Prism 4, La Jolla, California) with Tukey’s post-test.  
Concentration dependent GAP activity of RGS2 (Fig.3.11) was analyzed by nonlinear 
regression using a sigmoidal curve fit with a variable slope (GraphPad Prism 4, La Jolla, 
California).  P value of <0.05 was used to subscribe statistical significance. 
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Results 
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3.1 Region of RGS2 interaction on eIF2Bε:  
The interaction between RGS2 and eIF2Bε was first detected based on a yeast two-
hybrid screen from mouse brain library, where full length RGS2 was used as a bait to 
probe for novel interaction partners 
15
.  There were several positive results from this 
screen, and one that occurred several times was a forty five amino acid sequence that 
matched exactly the C-terminal region of eIF2Bε.  These stretches of sequence make up 
about the first two and half alpha helices of the catalytic domain of eIF2Bε, and therefore 
in the present study this region comprising forty five amino acids of human eIF2Bε was 
either removed all together (Δ1,2,3) or each helix deleted individually (Δ1 or Δ2) (Figure 
3.2). 
 
To assess the ability of mutants to interact with purified RGS2, plasmids containing 
eIF2Bε or internal deletion mutants were transfected into human embryonic kidney (HEK 
293) cells.  Subsequently, the cells were lysed, and purified RGS2 was added to the lysate 
for co-immunoprecipitation assays.  His/c-myc-tagged eIF2Bε was immunoprecipitated 
using an anti c-myc antibody and the mutants were then assessed on a western blot for the 
presence of eIF2Bε and RGS2 (both eIF2Bε and RGS2 are His-tagged so both can be 
visualized at the same time using an anti polyhistidine antibody) (Fig.3.1). 
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Figure 3.1 Co-immunoprecipitation using HEK293 lysates transfected with eIF2Bε and 
purified RGS2 
Co-immunoprecipitation assay was carried out by combining lysates from HEK293 cells 
transfected with a plasmid encoding His/c-myc eIF2Bε and mixing with purified His RGS2.  The 
cells were incubated for 48 hrs and lysed with lysis buffer.  Purified RGS2 (10 µg) was added to 
lysate (500 µg total protein) and incubated for 1hr at 4°C, then subsequently anti c-myc antibody 
plus protein A/G beads were added and incubated overnight.  The beads were then isolated by 
centrifugation and proteins were separated by SDS-PAGE followed by transfer onto PVDF 
membranes and immunoblotting.  The results are representative of two independent experiments.   
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Figure 3.2 Co-immunoprecipitation using HEK293 lysates transfected with eIF2Bε/internal 
deletion mutants and purified RGS2 
A) WT eIF2Bε and mutant constructs.  The putative binding domain spans about two and half α 
helices.  B) HEK293 cells were transfected with His/c-myc eIF2Bε and different internal deletion 
mutant constructs.  The cells were incubated for 48 hrs and lysed with lysis buffer.  Purified His 
RGS2 (10 µg) was added to lysate (500 µg total protein for the WT and 1.5 mg total protein for 
the internal deletion mutants) and incubated for 1hr at 4⁰C, then subsequently anti c-myc 
antibody plus protein A/G beads were added and incubated overnight.  The beads were then 
isolated by centrifugation and loaded onto SDS-PAGE. The input (lane 3) shows the signal 
obtained by adding 1 μg of purified RGS2 (i.e., 10% of the amount added to lysates) directly to 
the gel. The results are representative of three independent experiments. 
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A. 
 
 
B. 
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Figure 3.3 Co-immunoprecipitation of eIF2Bε transfected HEK293 lysates and purified 
RGS2. Densitometry analysis of the Co-IP shown in Figure 3.2B and two other replicate 
experiments. One way ANOVA was used to analyze statistical significance. 
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The result shows that the ability of all mutants to interact with RGS2 is visibly 
reduced compared to wild type (Fig.3.2B)  However there are technical limitations to this 
assay in that purified RGS2 became entrapped and/or bound nonspecifically to the 
protein A/G beads which was used to immunoprecipitate the protein complex (see lane 1 
in Figure 3.2B).  Therefore for densitometry, RGS2 levels were subtracted from the 
pcDNA transfection control before calculating the percentage bound to eIF2Bε (Figure 
3.3).  In addition mutant proteins expressed at approximately one-third that of the wild 
type (data not shown), making it difficult to control precisely the amount of eIF2Bε and 
mutants being added to each experimental group.  To compensate for the difference in 
proteinexpression levels between wild type and the mutants, three times the the total 
protein were added for mutant conditions.  Therefore another assay was used to further 
assess the physical interaction between RGS2-eIF2Be and also to address the issue of 
nonspecific binding as well as expression level of eIF2Bε mutants. 
 
3.2 Purification of eIF2Bε wild type and mutants variants from E.coli: 
            E.coli strain BL 21 (DE3) was used to express eIF2Bε and its mutants.  Purifying 
the protein instead of transfecting those into HEK cells allows us to better control the 
amount of protein being added into each assay group.  In addition, this would allow for 
the confirmation that eIF2Bε directly interacts with RGS2 by performing pull down 
assays. 
  
From the co-immunoprecipitation assays shown above (Figures 3.2B and 3.3), it 
was difficult to conclude with certainty that the loss of binding is due to removal of 
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domains that are crucial for interaction, as it is possible that the internal deletions may 
have affected the folding of the protein.  To address this issue, a series of N-terminal or 
C-teminal truncation deletions was made and tested. This region of the protein is known 
to function as a binding site for other subunits of eIF2B.  Even with N-terminal or C-
terminal truncation, there still remains the possibility that the constructs may not fold 
properly.  However, if these truncation mutants are able to interact with RGS2, we can 
confirm that the putative binding is sufficient for interaction and is likely in the proper 
conformation.. 
For purification, cDNA encoding human eIF2Bε or a variant thereof was 
subcloned into a pGEX vector to construct a fusion protein containing an N-terminal 
Glutathione S Transferase (GST) tag.  The plasmid was then transformed into E.coli 
strain BL21 (DE3) and expression was induced with a lactose metabolite analog (IPTG).  
The bacteria were lysed using sonication, and the protein of interest purified using 
glutathione sepharose 4B beads.  The purified proteins were visualized following SDS-
PAGE and Coomassie staining (Figure 3.4).  
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Figure 3.4 GST fusion protein expression 
A) Wild type eIF2Bε and truncation mutants were cloned in pGEX –vector and expressed and 
purified from E.coli BL21 (DE3).  Green colour indicates the 45 a.a. RGS2 binding domain.  B) 
Coomassie stain of purified proteins.  Alternating lanes containing the purified proteins with and 
without thrombin treatment to assess the ability of the GST tag to be cleaved. 
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3.3 Binding of purified eIF2Bε WT or truncation mutants to purified RGS2 
The RGS2 binding capabilities of purified eIF2Bε proteins were assessed using 
pull down assays via glutathione sepharose 4B beads.  GST protein was used as a control 
in order to verify that purified RGS2 bound to eIF2Bε and not to the GST tag.  These 
purified proteins were used to ascertain whether or not there is direct interaction between 
eIF2Bε and RGS2.  N-terminal and C-terminal truncations were made flanking the forty 
five amino acid putative RGS2 binding domain, until about thirty five amino acids were 
left N-terminally to the putative binding region (illustrated in Figure 3.4A). At least thirty 
five amino acids were left between the N-terminal GST tag and the putative RGS2 
binding domain as a precaution due to the possibility of steric hindrance arising from the 
size of GST moiety, which consists of over two hundred amino acids.  GST-pulldown 
assay was used to assess the ability of GST-eIF2Bε and truncation mutants to bind to 
purified His RGS2 (Figure 3.5).                         
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Figure 3.5 GST-pulldown assay between N/C truncated GST-eIF2Bε and His RGS2 
Purified His-RGS2 (1µM) was added to purified GST proteins (150 nM) plus glutathione beads 
and incubated at 4C for 1 hr prior to centrifugation. Lanes 1-5 are GST fusion proteins 
containing different eIF2Bε N/C-terminal truncation mutants. Lane 1 shows negative control 
using GST; lane 2 shows wild type GST-eIF2Bε (positive control), while lanes 3-5 show different 
N/C-terminal truncation mutants. This blot is representative of one of three independent 
experiments.     
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We found that RGS2 can bind to all of the different types of truncation mutants 
that we generated, thereby confirming the yeast two-hybrid data that RGS2 binding 
domain of eIF2Bε lies near the C-terminus.  In comparison with wild-type eIF2Bε and 
the other two truncation mutants, GST-300 a.a. binding to RGS2 appeared to be reduced 
(Figure 3.5).  From the blot however, it is evident that the lane showing GST-300 a.a. has 
greater proportion of free GST present compared to other fusion constructs.  This implies 
that a portion of free 300 a.a. fragments was also present in the solution before the 
pulldown took place.  Since any RGS2 that may bind to this tag free form of GST-300 
a.a. will not be recovered via glutathione sepharose beads, we would not expect to 
observe this interaction on the western blot.  Therefore, for subsequent pulldown assays 
(Figure 3.7B) we generated a modified version of this construct where we attached a 
different N- terminal amino acid to the GST tag in order to create greater stability during 
pulldown assay.  In the modified version of the GST-300 contruct, the first methionine 
plus four subsequent amino acids of eIF2Bε were attached to the GST tag instead of 
isoleucine 431.  
 
 This assay addresses the possibility of protein misfolding due to internal deletion 
from Figure 3.2B and confirms that forty five amino acid putative RGS2 binding domain 
is indeed important for interaction between eIF2Bε and RGS2.  The results obtained from 
Figure 3.2B and 3.5 suggest that eIF2Bε can directly interact with RGS2 in vitro and that 
the RGS2 binding domain on eIF2Bε lies near its C-terminus.     
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3.4 Amino acid substitution of residues within the putative RGS2 binding domain of 
eIF2Bε:  
From section 3.1 to 3.3 we confirmed that a 45 amino acid stretch near the eIF2Bε 
C-terminus is important for binding to RGS2.  Therefore we further investigated which 
residues within this region might contribute to binding.  To do this we employed a single 
amino acid substitution method.  From previous studies, we know that there are 
conserved residues near the C-terminus of eIF2Bε that are involved in promoting guanine 
nucleotide exchange on eIF2 
45
.  Of those, it is known that eIF2Bε residue leucine 576 is 
conserved throughout different species, and in its substitution to other residues results in 
stunted growth 
46
.  Based on the binding data from Figures 3.3 and 3.5, it appears that the 
forty five amino acid stretch identified from the yeast two-hybrid data is indeed important 
for binding to RGS2.  This region evidently also coincides with the region responsible for 
facilitating guanine nucleotide exchange 
48
.  Therefore I investigated whether mutation of 
these specific residues within this region would have an effect on the binding to RGS2.  
We chose residue leucine 576 and another conserved residue tyrosine 585, both of which 
according to crystal structures are at the surface of the protein and are not involved in 
folding of structure 
47
.  We mutated both residues to tryptophan which is a relatively large 
residue that would be expected to serve as a steric hindrance for interaction.  Other 
investigators have used an alanine mutation for leucine 576 
46
, however we chose 
tryptophan instead because of its larger molecular size, and hence it would be easier to 
see an effect if this site is indeed important for interacting with RGS2.  Subsequently 
these mutants were transfected into HEK 293 cells and the cell lysates were used to 
assess interactions with RGS2 in co-immunoprecipitation assays (Figure 3.6). 
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Figure 3.6 Co-immunoprecipitation assay between eIF2Bε/substitution mutants in lysates 
from transfected HEK 293 cells and purified RGS2 
The cells were incubated for 48 hrs and lysed with lysis buffer.  Purified RGS2 (10 µg) was 
added to lysate (500 µg total protein) and incubated for 1hr at 4⁰C, then anti c-myc antibody plus 
protein A/G beads were added and incubated overnight.  The beads were then isolated by 
centrifugation followed by additional washes comprising resuspension and recentrifugation.  The 
resulting samples were mixed with denaturing sample dye and loaded onto SDS-PAGE. The blot 
represents results of two independent experiments. 
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Tryptophan substitution at eIF2Bε residue 576 seems to reduce binding while 
mutation at residue 585 had no appreciable effect (Figure 3.6).  Our previous functional 
data indicate that eIF2 and RGS2 may compete for binding to eIF2Bε 15, and this 
experiment taken together with results from Figures 3.3 and 3.5 further suggests that 
RGS2 and eIF2 may share common binding motifs. 
 
3.5 Effects of mutating eIF2Bε phosphorylation sites on its binding to RGS2  
Since the region of binding has been established, we looked next into the effect of 
phosphorylation on ability of eIF2Bε to interact with RGS2.  As mentioned above in 
Section 1.5, there are at least five known phosphorylation sites on eIF2Bε, four of which 
play a role in modulating its effects on eIF2 
50
.  Two of the phosphorylation sites are 
targeted by GSK3 (Ser540) and an associated priming kinase (Ser544), while two other 
residues near the C-terminus are phosphorylated by CK2.  Phosphorylation by GSK3 is 
known to decrease the activity of eIF2B 
49
 while phosphorylation by CK2 seems to be 
essential for eIF2Bε’s ability to interact with eIF2 50.  In order to assess the effects of 
phosphorylation of the GSK3-associated residues on eIF2Bε binding affinity to RGS2, 
point mutations were made to change these serine residues to alanine (to mimic non-
phosphorylated state) or glutamic acid (to mimic phosphorylated state).  The mutants 
were then tested using pull down assays and immunobloting to probe for the presence of 
RGS2 (Figure 3.7 and 3.8).  Since GSK3 is known to decrease protein synthesis, we 
predicted that phosphorylation by GSK3 and its associated priming site would increase 
the binding of eIF2Bε to RGS2. 
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Figure 3.7 GST-pulldown assay between purified eIF2Bε GST-300/substitution mutants at 
the GSK3 site and RGS2 
Purified RGS2 (1 µM) was added to purified eIF2Bε-GST fusion proteins (300 nM) plus 
glutathione beads and the mixture was incubated at 4°C for 1hr prior to centrifugation. A) GST-
300 constructs with substitution mutation on phosphorylation sites.  Ser544 is phosphorylated by 
a priming kinase called dual tyrosine regulated kinase (DYRK), while Ser540 is the GSK3 site. 
These residues were replaced with either alanine or glutamic acid residues to mimic respectively 
the nonphosphorylated and phosphorylated states of the protein B) Immunoblot probing for the 
presence of His-RGS2 and GST and GST fusion proteins. 
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Figure 3.8 GST-pulldown assay between purified eIF2Bε GST-300/substitution mutants at 
the GSK3 site and RGS2 
Densitometry analysis of the pulldown assay.  The scale of y-axis is background (GST, lane2) 
normalized to one.  AA represents alanine mutations at GSK3 site while EE represents glutamic 
acid mutations. The results are averages from three independent experiments. 
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From densitometry analyses, it appears that the state of phosphorylation of 
eIF2Bε at the GSK3 site does not significantly affect the affinity of binding compared to 
wild type (Figure 3.8).  However this observation may not necessarily rule out the 
significance of phosphorylation by GSK3 on RGS2’s interaction with eIF2Bε.  One of 
the limitations of using a mammalian protein that has been purified from bacterial 
systems is that the product may not have all of the post translational modifications that 
the protein would usually acquire if it was expressed in a mammalian system.  Some 
proteins are required to undergo more than one post-translational modification in order 
for one to observe changes in binding affinity, and additionally other cellular constituents 
may exist that affect the ability of two proteins to interact.  For example Wang et al. have 
shown that in order for GSK3 to efficiently target eIF2Bε, a priming serine site four 
amino acid downstream must first be phosphorylated 
49
.  They have also shown that when 
the last sixty amino acids of eIF2Bε were removed, it significantly decreased its 
capability to bind GSK3.  Similarly, it is possible that RGS2 may require a “priming” 
mechanism before it can efficiently interact with eIF2Bε in response to phosphorylation 
by GSK3.  In addition, since RGS2 appears to compete with eIF2 for binding to eIF2B, a 
change in eIF2B that alters its binding to cellular eIF2 might indirectly affect RGS2-
eIF2B binding.  Therefore, to test this hypothesis we carried out interaction studies using 
a mammalian expression system to compare the binding of RGS2 to eIF2Bε and its 
phosphorylation mimic at its GSK3 site. 
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3.6 Co-IP of RGS2 and eIF2Bε phosphorylation mutants expressed in mammalian 
cells 
Cells expressing either wild type eIF2Bε or mutants with either alanine or 
glutamic acid substitutions at residues 540 and 544 were lysed and mixed with purified 
His RGS2.   A co-immunoprecipitation assay was then performed in order to assess the 
effect of these substitution mutations on binding (Figure 3.9).     
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Figure 3.9 Co-immunoprecipitation of eIF2Bε/substitution mutants from transfected 
HEK293 cell lysates and purified RGS2 
A) HEK293 cells were transfected with eIF2Bε or substitution mutant constructs (illustrated in 
Figure 3.4A).  The cells were incubated for 48 hrs and lysed with lysis buffer.  Purified RGS2 (10 
µg) was added to lysate (500 µg total protein) and incubated for 1hr at 4°C, then subsequently 
anti c-myc antibody plus protein A/G beads were added and incubated for 3hrs.  The beads were 
centrifuged, washed three times with lysis buffer and loaded onto SDS-PAGE.  100 ng of RGS2 
were loaded directly onto the gel in the input lane. B) shows densitometry analysis of Co-IP 
assay.  The scale of y-axis is RGS2/eIF2Bε bound normalized to one.  AA represents alanine 
mutation on GSK3 site while EE represents glutamic acid mutation. The results are acquired from 
three independent experiments and were analyzed using the unpaired T-test. 
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From densitometry analysis eIF2Bε with a phosphorylation mimic at its GSK3 
site appears to bind significantly better to RGS2 than eIF2Bε either with alanine 
mutations of the same site or with no mutations (Figure 3.9).  This was consistent with 
findings from other labs that the activity of eIF2Bε is decreased when it is 
phosphorylated by GSK3 and the finding in our lab that RGS2 interacting with eIF2Bε 
decreases translational efficiency 
49
 
15
.  However in order for a direct link to be 
established we will need to further examine the effect of binding on the activity of eIF2B 
by using a functional readout such as an in vitro translational assay.    
 
3.7 Effect of eIF2Bε on RGS2 GAP activity:  
From previous work done in our lab, we know that RGS2 can interact with 
eIF2Bε and decrease global protein synthesis 15.  However it is not known whether or not 
eIF2B reciprocally produces an effect on RGS2 activity. Here we investigated the 
possibility that interaction between these two proteins can affect the GTPase accelerating 
protein (GAP) activity of RGS2.  To test this we employed a steady state GTP hydrolysis 
assay.  Using a baculovirus expression system, M1 muscarinic receptor fused to Gα11 
was co-infected with Gβγ into SF9 insect cells, followed by lysis and separation of 
membrane components from supernatant.  The membrane fraction containing the GPCR 
and G-proteins was mixed with RGS2 alone or RGS2 with GST-300 fusion 
protein/substitution mutants.  Receptor stimulated GTP hydrolysis was measured using 
radio labeled GTP as a tracer.         
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Here we used RGS2 at 1µM and GST-300 protein at varying concentrations in 
order to see whether the presence of GST-300 can affect RGS2’s ability to promote GTP 
hydrolysis and whether GST-300 can affect its GAP activity in a dose dependent manner 
(Figure 3.10).   
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Figure 3.10 Effect of GST-300 on RGS2 GAP activity 
Purified RGS2 (1 µM) was first mixed with purified  GST protein and GST-300 a.a. Carbachol 
and Sf9 cells membrane containing Muscarinic receptor and G-proteins were then added to the 
mixture, followed by incubation at 4°C for 1hr before radiolabeled GTP was added to the 
mixture. The reaction was allowed to go for 5 min at 30°C and subsequently stopped with 
activated charcoal, and counting the radioactivity was done using a liquid scintillation counter.  
This is the result of two independent experiments carried out in triplicates. The data were 
analyzed using one-way ANOVA followed by Tukey’s multiple comparison test.    
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At all concentrations tested, GST-300 protein did not have any appreciable effect 
on the ability of RGS2 to promote GTP hydrolysis (Figure 3.10).  One possible 
interpretation of this finding is that we couldn’t see any effect because the RGS2 GAP 
capability is already saturated at 1 µM 
57
.  Therefore instead of varying the GST-300 
concentration, we decided to measure the effect of GST-300 at 300 nM on varying 
concentrations of RGS2 (Figure 3.11).  Therefore since RGS2 GAP activity would not be 
saturated when being tested at lower concentrations, it would be easier to see an effect if 
GST-300 can interfere or enhance the ability of RGS2 to promote GTP hydrolysis.     
 
Results from the GAP assays (Figures 3.10 and 3.11) suggest that GST-300 does 
not have any significant effect on the ability of RGS2 to promote GTP hydrolysis.  This 
is contrary to our hypothesis since translation efficiency decreased in the presence of 
RGS2, and we postulated that eIF2Bε binding to RGS2 would affect RGS2 GAP activity 
on Gq. 
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Figure 3.11 Effect of GST-300 on RGS2 GAP activity version 2 
Purified RGS2 at the concentrations indicated was first mixed with purified GST protein or GST-
300 a.a. (300 nM).  Carbachol and Sf9 cells membranes containing Muscarinic receptor and G-
proteins were then added to the mixture, followed by incubation at 4°C for 1 hr before 
radiolabeled GTP was loaded into the mixture. The reaction was allowed to proceed for 5 min at 
30°C and subsequently stopped with activated charcoal and radioactivity was assessed using a 
liquid scintillation counter.  This is the result of three independent experiments carried out in 
triplicates.  The data was analyzed using one-way ANOVA followed by Tukey’s multiple 
comparison test.    
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Chapter 4 
Conclusion and Discussion 
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4.1 Summary of Findings 
Previously we have shown that RGS2 is able to interact with eIF2Bε via co-
immunoprecipitation of overexpressed proteins as well as endogenous proteins in 
mammalian cells 
15
.  Here, using a pulldown assay, we have established that purified 
eIF2Bε can directly bind to purified RGS2 (Figure 3.5), and that the RGS2 binding 
domain of eIF2Bε lies near its C-terminus (Figures 3.3 and 3.5).  It appears that the 45 
amino acid putative binding domain originally identified in the RGS2 yeast two-hybrid 
screen is important for binding though there may be other regions on eIF2Bε that may 
play a role in its interaction with RGS2.  Within this putative binding region we have 
found that leucine 576 is crucial for binding while tyrosine 585 is not (Figure 3.6).  
Experiments from interaction assays using phosphorylation mimic eIF2Bε substitution 
mutants have yielded different results.  On one hand a GSK3 site phosphorylation mimic 
did not bind any better than wild type or a corresponding alanine mutation in a pull-down 
assay using both purified eIF2Bε and RGS2 (Figure 3.8).  However when eIF2Bε was 
overexpressed in HEK293 cells and co-immunoprecipitated with purified RGS2 we 
found that the GSK3 site phosphorylation mimic was able to bind significantly better 
than the alanine mutation (Figure 3.9).  Lastly purified eIF2Bε did not have a significant 
effect on the GAP activity of RGS2 (Figures 3.10 and 3.11).     
 
4.2 Significance of Research: 
RGS2 was first discovered as a protein that accelerates the GTP hydrolysis on G 
proteins of the Gq subfamily, attenuating their signaling duration 
22
.  However recent 
findings by our lab have added to the case that RGS2 has a broader role in cell function.  
By further investigating the interaction of RGS2 with eIF2B and the cellular pathways 
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that have the potential to regulate this interaction, we may gain further insight into the 
role of RGS2 in regulating translation, as well as gaining insight into the physiological 
relationships between the cell signaling pathways involved.      
 
4.3 Interaction between G-protein signaling and mRNA translation systems: 
There have been clues from other published studies in the past that point to 
potential links between G protein signaling and cellular protein synthesis.  For example 
there has been the observation that the α subunit of eIF2B can interact with the carboxyl 
tails with α2A-, α 2B-, α 2C-, and β2-adrenergic receptors, and effect a 15% increase in 
adenylyl cyclase activity as a consequence 
61
. Another group has also identified eIF2Bα 
as being a potential candidate that may interact with adrenergic receptor subtypes via 
forming protein complexes with 14-3-3 
62
.  We also know that RGS2 can interact with 
14-3-3 (M. Abramow-Newerly, H. Ming and P. Chidiac unpublished observation) and 
with several GPCRs via the scaffolding protein spinophilin 
63
, including receptors that 
can also interact with the translational machinery, namely the  α2A-, α 2B-, and α 2C-
adrenergic receptors 
64
.  From our previous studies we found that RGS2 interacts with 
eIF2B, demonstrating this relationship using overexpressed system as well as endogenous 
co-immunoprecipitation.  In addition RGS2 can inhibit protein synthesis based on in vitro 
translation and leucine incorporation assays.  Consistent with this, hepatocytes from 
RGS2
-/-
 displayed an elevated level of protein synthesis compared to that of wild type 
15
.   
 
Taken together these results show that we have come across a novel mechanism 
whereby protein synthesis can be regulated and controlled.  In addition, the web of 
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interactions between these proteins suggests the idea that there might be local controls of 
mRNA translation taking place at the plasma membrane due to associations with 
signaling proteins, as well as vice versa where G-protein signaling may be modulated by 
translational machinery.  
 
4.4 Characterizing the region of binding 
Here in outlined by the results, we have further investigated this interaction by 
characterizing the region on eIF2Bε that is responsible for its binding to RGS2.  We also 
examined phosphorylation sites on eIF2Bε and their effects on binding affinity as well as 
functional consequences of the interaction.  In regard to the region of binding, we have 
found that the 45 amino acid region indicated by our earlier two-hybrid screen is indeed 
important for interaction, as shown by a loss of co-immunoprecipitation with internal 
deletion mutants lacking this part of the protein as opposed to successful GST-pull down 
assays with N-terminal truncation mutants that contained it (Figures 3.3 and 3.5).  The 45 
amino acid regions comprises two and half α helices, of which the first two are exposed 
to the surface of eIF2Bε 47.  Additional experiments were carried out to reinforce the data 
generated by internal deletion method, the interpretation of which is limited by the 
possibility that the loss of binding might stem from improper folding of protein structure 
as the result of the mutation.  To further the study, we used N-terminal truncation in 
conjunction with internal deletion mutant data to show that the 45 region is indeed 
sufficient for interaction with RGS2 (Figures 3.5).  We however did leave about 35 
amino acid N-terminal to this region because the construct was fused to GST tag and 
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potentially the tag might sterically mask the region of binding from eIF2B, given that the 
tag itself comprises of more than 200 amino acid.     
 
The 45 amino acid stretch that interacts with RGS2 is located within the C-
terminal region of eIF2Bε and it overlaps with the domain responsible for promoting 
guanine nucleotide exchange on eIF2.  This is consistent with our previous data and 
provides an explanation why RGS2 can apparently compete with eIF2 and decreases the 
guanine exchange factor (GEF) activity of eIF2B in a dose dependent manner 
15
.  Within 
this region there are multiple residues that are known to be important in contributing to 
the GEF activity of eIF2B, as these residues are either conserved or identical throughout 
many different species of mammals, plants, and yeast 
45
.  We therefore mutated residues 
within 45 putative binding domain and tested them in co-immunoprecipitation assay.  We 
picked leucine 576 and tyrosine 585 as a starting point because leucine 576 has been 
shown to play an important role in binding to eIF2 and is conserved throughout different 
species, while tyrosine 585 is also a conserved residue among mammalian species and is 
a possible candidate for phosphorylation 
46
.  Based on available crystal structural data of 
the last 200 amino acid, it appears that both leucine 576 and tyrosine 585 are exposed to 
the surface of the protein and neither seems to contribute to the folding of the secondary 
and tertiary structure 
47
.  The putative binding site spans two and half alpha helices and 
the surface of the interaction is localized to one clustered area.  There are other sites on 
this surface that may be important for binding like glutamic acid 577 and arginine 567, 
which is conserved in many species 
45
.  Crystal structure reveals that this residue 
glutamic acid 577 makes contact with arginine 567 and forms an acid-base ionic 
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interaction, and may potentially contribute to the stability of the tertiary structure; hence 
we did not mutate these residues (Figure 4.1) 
47
.                   
 
From the binding data we have found that mutation at leucine 576 to a tryptophan 
adversely affects the binding to RGS2 while mutation at tyrosine 585 to tryptophan does 
not have any appreciable effect on binding (Figures 3.6).  Based on substitution mutant 
data we have identified at least one residue that appears to be essential for interaction 
with RGS2.  Likely there are more residues that are important for interaction within this 
region, and we would like to explore these further in future studies.  However the data 
from leucine 576 mutation taken together with the internal deletion and N-terminal 
truncation experiments confirms that this region of eIF2B is required for its interaction 
with RGS2 and implies that the presence of leucine 576 is essential. 
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Figure 4.1 Conserved amino acid residues within the putative RGS2 binding domain on 
eIF2Bε 
A) Crystal structure of C-terminal domain of eIF2Bε with putative RGS2 binding domain 
highlighted in yellow. The C-terminus lies at the left side of the figure while the N-terminus is on 
the right B) Leucine 576 (left) and tyrosine 585 (right) were mutated to tryptophan, both 
highlighted in yellow.  
 
Figure was obtained from Pubmed, and crystal structure is from Protein and Cell (2010) 
Jun;1(6):595-603. Crystal structure of the C-terminal domain of the ɛ  subunit of human 
translation initiation factor eIF2B.  
Wei J, Jia M, Zhang C, Wang M, Gao F, Xu H, Gong W. 
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4.5 Phosphorylation sites 
We examined the potential importance of the glycogen synthase kinase 3 (GSK3) 
phosphorylation site because it lies only 14 amino acid residues away from the putative 
RGS2 binding domain in human eIF2Bε.  In contrast, casein kinase 2 (CK2) lies 109 
amino acid downstream of the binding domain and therefore we did not pursue this site in 
the present study.  In addition, we found that our GST-80 construct lacking the CK2 site 
but containing the GSK3 was still able to interact with RGS2, therefore the GSK3 
phosphorylation site was considered to be more likely to modulate RGS2 binding (Figure 
3.5).  From the literature it is known that phosphorylation by GSK3 decreases the activity 
of eIF2B 
53
.  Since we have found that RGS2 can also bind and decrease eIF2B activity 
15
 
and the binding site lies close to GSK3 site, we asked if there might be any point of 
convergence between RGS2 and GSK3 or whether phosphorylation by GSK3 might 
promote the binding of RGS2 to eIF2B.   Phosphorylation is a common mechanism in the 
cell whereby protein structure and surface charge can be altered so that the 
phosphorylated protein’s affinity to its binding partners can be either enhanced or 
decreased.  Phosphoserine is structurally similar to that of glutamic acid as well as the 
negative charge that the phosphate group possess similar to that of negative charge found 
on the acidic side chain.   
 
Based on the foregoing we used glutamic acid as a substitute to mimic the 
phosphorylated state of serine and alanine to mimic the non-phosphorylated state.  One 
interesting mechanism for GSK3 kinase function is that the target amino acid residue 
generally requires another priming site to be phosphorylated in order for GSK3 to 
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efficiently work 
49
.  Therefore we mutated both the priming and target site to either 
glutamic acid or alanine.  However when we tested these mutants in a GST-pull down 
assay we found that the binding affinities of both mutants were similar to wild type 
(Figures 3.7 and 3.8).  At first we concluded that perhaps phosphorylation of these sites 
might not modulate the affinity of eIF2Bε to RGS2.  However because we noted how 
GSK3 requires priming site and it also requires the C-terminus of eIF2Bε to efficiently 
phosphorylate its target site, it is conceivable that simply mutating these sites might not 
be sufficient.  We speculated that perhaps other modifications could be required in order 
for RGS2 to interact with eIF2B with higher affinity. This is because when a protein is 
purified from a bacterial system the resulting product could lack post-translational 
modifications including phosphorylation, which would be present if the protein was 
expressed in a mammalian system.   
 
We repeated this assay instead using eIF2Bε and its mutants in HEK293 cells.  
The result from the alternative technique showed a significant difference between the 
glutamic acid and alanine mutations, and it appears that glutamic acid mutants bound 
better to RGS2 than either the alanine mutant or the wild type (Figure 3.9).  This would 
appear to support our original hypothesis that other sites must be modified as a 
prerequisite in order for eIF2Bε interacting with RGS2 at higher affinity; though to 
confirm this we still would need to identify and test other post-translational modification 
sites on eIF2Bε. 
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Proud et al. found that when rabbit reticulocyte lysates were preincubated with 
GSK3, eIF2B GEF activity was significantly decreased compared to control 
49
.  In 
addition, this decrease in activity was still observed when they partially purified eIF2B 
using ion-exchange chromatography prior to incubation with GSK3.  Therefore it was 
thought that the reduction in activity likely arose from a decrease in the intrinsic activity 
of eIF2Bε rather than altering of binding to a different regulator.  Nevertheless, it is 
possible that phosphorylation of eIF2B may lead to a more favorable interaction with an 
alternate binding partner or alternatively a decrease in affinity to eIF2.  Based on our 
observation phosphorylation mimic on GSK3 site resulted in better binding of eIF2Bε to 
RGS2 compared to non-phosphorylation mimic (Figure 3.9).  One possible explanation is 
that phosphorylation mimic induces a more favorable conformation for eIF2Bε to be able 
to bind RGS2.  Alternatively, phosphorylated eIF2Bε’s affinity for endogenous eIF2 may 
be decreased, resulting in less competition from eIF2 and therefore increased RGS2 
binding. 
 
 The data we obtained may provide a possible explanation and link between 
GSK3 and RGS2.  Since both proteins affect decreases in protein synthesis, it is plausible 
that GSK3 phosphorylation provides a favorable structural and surface charge change for 
RGS2 to bind to eIF2Bε.  However the data is purely correlational and further 
investigation is required if cause-effect is to be established. 
 
As mentioned in the Introduction, to date there are five known phosphorylation 
sites that have been identified on eIF2Bε; GSK3, dual tyrosine regulated kinase (DYRK) 
81 
 
 
 
which is the priming site for GSK3, CK1, and CK2 which consists of two 
phosphorylation sites.  GSK3 phosphorylation decreases eIF2B activity; CK2 
phosphorylation is necessary for eIF2B and eIF2 interaction, while the effect of CK1 
phosphorylation is controversial 
50
.  Regardless of the effect of each phosphorylation 
there is a common pattern underlying the positioning of these sites.  It may be noted that 
within the eIF2Bε protein sequence, these sites are located near acidic residues motifs or 
in the case of CK2 they are embedded in acidic residue rich motifs.  In the case of the 
CK2 sites for example, two serine residues are flanked by a glutamic acid and two 
aspartic acids toward the N-terminus and three glutamic acids toward the C-terminus.  
These phosphorylation sites therefore may provide a means of modulation for C-terminal 
tail of eIF2Bε to bind better to the lysine rich motifs of eIF2 44.  Apart from the five sites 
identified so far there are five more serine residues located near the GSK3 site N-
terminally that may also be potential phosphorylation sites.  Three of these sites are 
embedded in glutamic acid motifs which if phosphorylated would be expected to 
strengthen the acidic motif.  It would be of interest whether mutating these sites to 
glutamic acid could change the binding affinity of eIF2Bε to RGS2, provided that these 
sites can first be identified as phosphorylation sites.        
  
4.6 Functional consequences of binding 
From previous work in our lab we have found that RGS2 can inhibit protein 
translation by binding to eIF2Bε 15.  We then asked the next obvious question: does 
eIF2Bε binding to RGS2 have any effect on its ability to promote GTP hydrolysis by 
heterotrimeric G proteins?  At first we used RGS2 at 1 µM with varying concentration of 
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GST-300 construct.  However at all concentrations tested GST-300 did not have any 
significant effect on the GTP hydrolysis accelerating (GAP) activity of RGS2 compared 
to control (Figure 3.10).  However we know that the GAP activity of RGS2 is already 
saturated at this concentration, so we reasoned that using lower concentrations of RGS2 
might allow us to detect an effect of GST-300.  From RGS2 concentration dependence 
result we have found that the GST-300 construct still did not have a significant effect on 
RGS2 GAP capabilities (Figure 3.11).  This was somewhat unexpected since RGS2 
binding site for eIF2Bε partially overlaps with the RGS box which is responsible for the 
GAP activity of RGS2.  Since eIF2Bε is 80 kDa and RGS2 is 26 kDa, there is a chance 
that eIF2Bε would sterically hinder the interaction of RGS2 and Gα.   
 
However having done both interaction assays with eIF2Bε expressed in 
mammalian system as well as bacterial system, it seems that eIF2Bε obtained from 
mammalian cells may bind more strongly than the same protein obtained from a bacterial 
source.  Based on western blots and densitometry developed from co-
immunoprecipitation assay, RGS2 seems to bind stoichiometrically to eIF2Bε (Figure 
3.3). In contrast, GST-fusion eIF2Bε/truncation mutant proteins of 150 nM pulled down 
<100 ng (<16.67 nM) of RGS2, even though 1 µM of RGS2 was added to the reaction 
mixture (Figure 3.5).  The ratio of RGS2 bound to eIF2Bε from the co-
immunoprecipitation assay was about 50% while the RGS2 bound to purified eIF2Bε was 
less than 11%.  Therefore we interpreted our data with caution; since if RGS2 does not 
bind very well to purified eIF2Bε, it would appear that eIF2Bε has little to no effect on 
RGS2 GAP activity.  It would be helpful to have further data from analogous 
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experiments repeated with eIF2Bε expressed and purified from mammalian cells, as this 
form may bind to RGS2 better and an effect might be more easily observed.  The 
functional assay that was used to show the RGS2 inhibition of mRNA translation was 
performed using rabbit reticulocyte lysates, wherein RGS2 was purified from E.coli 
BL21 (DE3) while the eIF2B was from the reticulocytes 
15
.   
 
Another possible explanation for the observation is that the RGS2 can both bind 
to Gα11 and eIF2Bε simultaneously.  Although the binding site on RGS2 to eIF2Bε 
overlaps with first 37 amino acid residues of RGS2’s RGS box, the eIF2Bε binding 
domain may not actually face toward the surface of Gα based on the available co-crystal 
structure of triple mutant RGS2 and Gαi 65.   If this is the case then RGS2 may bind to 
eIF2Bε without compromising its interaction with Gα11 and subsequent GAP activity.      
 
4.7 Future Studies 
 The work presented in this thesis raises a number of issues.  We now know the 
region of eIF2Bε that associates with RGS2, and that phosphorylation of eIF2Bε at the 
GSK3 site increases the binding between the two proteins.  For future studies, it would be 
of interest to investigate if other phosphorylation sites near GSK3 site, such as serine 525 
can have an effect on RGS2-eIF2Bε interaction. We know that RGS2 also possess 
phosphorylation sites near its N-terminus 
21
, and therefore it would be worthwhile to 
investigate whether phosphorylation of RGS2 would have an effect on binding to eIF2Bε.  
In addition, we would like to pursue whether GSK3 may have a modulatory role in 
eIF2Bε activity through RGS2, and this would give us further insight into protein 
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interaction network.  To test this we can employ endogenous co-immunoprecipitation 
method and observe whether knockdown of GSK3 can affect the amount of RGS2 bound 
to eIF2Bε.     
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presentation.  “CHARACTERIZATION OF EIF2Bε AND ITS INTERACTION 
WITH RGS2” 
2. 12th Annual Great lakes GPCR retreat.  Montebello, Quebec 2011.  Abstract and 
oral presentation.  “CHARACTERIZATION OF EIF2Bε AND ITS 
INTERACTION WITH RGS2” 
Relevant Technical Experience 
-Cloning and site-directed mutagenesis 
-Genotyping 
-Bacterial expression of recombinant protein 
-Western blotting 
-SDS-PAGE 
-Reverse Transcriptase (RT) PCR 
-Real Time PCR 
-In vitro cell culture  
      
 
